<DOC>
	<DOCNO>NCT01288443</DOCNO>
	<brief_summary>Primary Objective : - To evaluate effect alirocumab ( SAR236553/REGN727 ) low-density lipoprotein cholesterol ( LDL-C ) level 12 week treatment comparison placebo participant LDL-C ≥ 100 mg/dL ( ≥ 2.59 mmol/L ) ongoing stable atorvastatin therapy . Secondary Objectives : - To evaluate effect alirocumab lipid level 12 week treatment comparison placebo - To evaluate safety tolerability alirocumab - To evaluate development anti-alirocumab antibody - To evaluate pharmacokinetics alirocumab</brief_summary>
	<brief_title>Efficacy Safety Evaluation Alirocumab ( SAR236553/REGN727 ) Patients With Primary Hypercholesterolemia Stable Atorvastatin Therapy</brief_title>
	<detailed_description>The duration study participation depend status participant screening : - For participant receive atorvastatin 10 mg , 20 mg , 40 mg stable dose least 6 week prior screen , study participation approximately 21 week include screen period 1 week , double-blind treatment period 12 week follow-up period 8 week . - For participant receive lipid-lowering treatment atorvastatin stable dose atorvastatin 10 mg , 20 mg , 40 mg least 6 week prior screen , drug naive participant , study participation approximately 27 week include screen period 1 week , run-in treatment period atorvastatin 10 mg , 20 mg , 40 mg stable dose 6 week , double-blind treatment period 12 week , follow-up period 8 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants primary hypercholesterolemia receive lipidlowering treatment atorvastatin stable dose atorvastatin 10 mg , 20 mg , 40 mg least 6 week prior screen period drug naive participant likely lowdensity lipoprotein cholesterol ( LDLC ) ≥ 100 mg/dL ( ≥ 2.59 mmol/L ) end 6week runin treatment period atorvastatin therapy OR Participants primary hypercholesterolemia treat atorvastatin stable dose 10 mg , 20 mg , 40 mg least 6 week prior screen period likely LDLC ≥ 100 mg/dL ( ≥ 2.59 mmol/L ) screen visit Exclusion criterion : 1 . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) : After runin period atorvastatin ( 10 mg , 20 mg , 40 mg ) participant receive lipidlowering treatment atorvastatin stable dose atorvastatin 10 mg , 20 mg , 40 mg least 6 week prior screen , drug naive participant OR At first visit participant treat stable dose atorvastatin ( 10 mg , 20 mg , 40 mg ) least 6 week prior screen 2 . Participants previously instruct cholesterollowering diet 3 . Participants type 1 diabetes 4 . Participants type 2 diabetes treat insulin 5 . Participants type 2 diabetes glycated hemoglobin ( HbA1c ) ≥ 8.5 % screen visit ( consider poorly control ) 6 . Laboratory finding measure randomization : Triglycerides ( TG ) &gt; 350 mg/dL ( &gt; 3.95 mmol/L ) screen visit Positive serum urine pregnancy test female childbearing potential 7 . Pregnant breastfeed woman 8 . Women childbearing potential effective contraceptive method The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>